Dr Ian Dunham, Open Targets director, presented Open Targets, a large-scale public-private consortium between leading organisations in bioinformatics, genomics, and pharmaceuticals. Open Targets has a vision of transforming the drug industry through the prioritisation and systematic identification of drug targets, the crucial first step in new drug discovery. Drawing on his nearly three decades of experience in the field, Dr Dunham discussed the ways data integration and pre-competitive collaboration across private and public organizations can accelerate drug discovery. The research will feed directly into the European Commission’s Open Science Monitor project, which seeks to value the impact and effect of open science.